News

A groundbreaking study demonstrates the long-term success of CD19 CAR T-cell therapy in treating patients with relapsed/refractory acute lymphoblastic leukemia (ALL) following allogeneic hematopoietic stem cell transplantation, offering new hope in hematology.

Bioocus is at the forefront of developing next-generation CAR-T therapies. The recent publication by Dr. Chunrong Tong and her team at Lu Daopei Hospital highlights critical advancements and challenges in the application of second-generation CD19 CAR-T therapies in pediatric patients, showcasing Bioocus's commitment to innovative cancer treatment.

A groundbreaking study highlights the remarkable effectiveness of CAR-T cell therapy in treating B-cell Acute Lymphoblastic Leukemia (B-ALL). The research, involving collaboration with BIOOCUS and Lu Daopei Hospital, demonstrates significant advancements, establishing the therapy as a critical treatment option.

Researchers from Lu Daopei Hospital and international collaborators explore cutting-edge CAR-T cell therapies, offering hope for patients with B cell malignancies. This study highlights advancements in design and application, showcasing promising results and the potential for future innovations.

Recent clinical studies reveal that 4-1BB-based CD19 CAR-T cells demonstrate superior antitumor efficacy compared to CD28-based CAR-T cells in treating relapsed or refractory B cell acute lymphoblastic leukemia (r/r B-ALL).

A recent study at Lu Daopei Hospital demonstrated the high efficacy and safety of low-dose CD19 CAR-T cell therapy in treating refractory or relapsed B acute lymphoblastic leukemia (B-ALL) patients. The research, which included 51 patients, showcased a remarkable complete remission rate with minimal side effects.

Lu Daopei Hospital and Hebei Senlang Biotechnology have announced promising findings from their recent study on the safety and efficacy of CAR-T therapy for acute B cell leukemia. This collaboration highlights the potential of novel CAR-T cell designs to enhance patient outcomes.

A new study led by Dr. Zhi-tao Ying from Peking University Cancer Hospital has demonstrated the safety and efficacy of IM19 CAR-T cell therapy in treating relapsed and refractory B-cell hematologic malignancies. Published in the Chinese Journal of New Drugs, the study reports that 11 out of 12 patients achieved complete remission with no severe adverse effects, showcasing the potential of IM19 as a promising treatment option for patients with limited alternatives.

Over the past five decades, research on Natural Killer (NK) cells has revolutionized our understanding of innate immunity, offering promising new avenues for cancer and viral therapies.

The 2024 Annual Training for Clinical Blood Management and Transfusion Technology in Sanhe City was successfully held at Yanda Ludaopei Hospital. This event aims to enhance clinical blood management and transfusion safety through comprehensive training sessions attended by over 100 healthcare professionals from various medical institutions.

A pioneering study at Erlangen University Hospital successfully treated a 16-year-old girl with severe systemic lupus erythematosus (SLE) using CAR-T cell therapy. This marks the first use of this treatment for pediatric lupus, offering new hope for children with autoimmune diseases.

A recent study in Nature Communications reveals key insights into the intrinsic signaling pathways that modulate the effectiveness of targeted protein degradation using PROTACs. This discovery could pave the way for more effective treatments for cancer and other diseases.